It's Time to Put the "e" in front of Specialty Prescribing, Benefit Verification and Prior Authorization



CEO & Managing Partner





Agenda


- What are specialty medications?
- What's the impact?
- How are they processed today?
- Where are we today?
 - ePA
 - Specialty ePrescribing
 - eBenefits Verification
 - REMS

What are Specialty Medications?



What are specialty medications?

- Usually injectable; 'large molecule' biological drugs ('biotech drugs')
- 'High' Cost (>\$600 per month)
- Require unusual or resourceintensive handling or dispensing processes (i.e. cold/frozen shipping; adjunct supplies like injection aids)
- Require focused clinical management



There is no commonly accepted definition.


FDB & Zynx Health Conference

What's the impact?



Specialty drugs continue to grow

- US spending on specialty drugs is projected to grow 67% by the end of 2015
- Specialty medications are the fastest-growing sector in the American healthcare system, expected to jump by two-thirds by 2015, and account for half of all drug costs by 2018
- Specialty medications can run at \$2,000 per month per patient; those at the high-end cost upwards of \$100,000 to \$750,000 per year




How are they processed today?




The current process





Today's prescribing process:

Obsolete. Inefficient.





Where are we?



ePrescribing









But ...

(

0%

of doctors know the medication is specialty 30%

of eRxs contain diagnosis code

0%

of doctors know where the specialty Rx should be dispensed 95%

of specialty Rxs prescriberpharmacy are faxed

50%-95%

specialty Rxs require Prior Authorization

95%


Opportunity for financial assistance for patients

5%-10%

Have REMS or MedGuides

Electronic Prior Authorization

- Retrospective and prospective models emerging in the marketplace
- Retrospective being conducted in a proprietary manner
- Industry movement toward prospective
- Prospective ePA officially approved as part of the SCRIPT standard in July, 2013
- Standardized retrospective process on-hold
- Standardized questions being addressed
- Need for standardization, evidence based PA criteria



Benefits Verification

- Today still done via phone/fax
- Effort to bring a standardized electronic benefit verification to the market via the Real-Time Benefit Inquiry
- Options include using:
 - NCPDP Telecommunications D.0 Standard
 - X12 270/271 Eligibility Request
 - NCPDP SCRIPT Standard

MC Real Time Prescription Benefit Inquiry Task Group Call Notes Scope of Real Time Prescription Benefit Inquiry Task Group:

- or near time Prescription benefit inquity rask Group:

 Recruit a wide range of implementer and standards subject matter experts to participate in
- 2. Define what constitutes the prescription benefit as reported by actors of the use case.
- 3. Focus the work of the task group solely on defining the Use Cases and Business Requirements of an NIBL SUMMON.

 Do not base these discussions on any of the existing standards so as not to be limited by current 5. The deliverable of the task group will be documentation of the Use Cases and Business
- The task group's scope is not to select a standards base or define a solution, though, these The task group's scope is not to select a standards base or define a solution, though, these documents will help guide NCPDP in a future discussion and direction on recommending a

REAL TIME PRESCRIPTION BENEFIT INQUIRY TASK GROUP LEADERS & NCPDP STAFF LIAISON


TASK GROUP CALL SCHEDULE

- Invites may be downloaded from the NCPDP Collaborative Calendar
- Bi-Weekly 60 Minute Calls on Thursdays (August 21, September 4, September 18, October 2, 11:00 AM PDT and AZ, 12:00 PM MDT, 1:00 PM CDT and 2:00 PM EDT Phone: 1-646-307-1300 code 111084
- Collaborative Work Space: http://dms.ncpdp.org/

Specialty ePrescribing

(

- Task Group formed during fall 2013 Workgroup Meeting
- Co-lead by Laura Topor and Tony Schueth
- Goal is to include data elements needed by specialty pharmacy in the original prescription
- Accomplishments include recommendations for:
 - Diagnosis Code
 - Patient Contact Information
 - Height/Weight
 - Inclusion of Patient Insurance Information
- Working on identifying other data elements that can be included in the transaction and means of transmittal



REMS




WG 1 – Telecommunications D.0


- Supports an "in workflow" REMS solution
- Currently supports a class-wide TIRF REMS (i.e. Transmucosal Immediate Release Fentanyl)
- Enhancements successfully balloted (Version E.3) for future use
 - Also supports real-time and in-workflow prescription drug monitoring program (PDMP) reporting

WG 11 – SCRIPT

- Standardizing the REMs process using ePrescribing transactions
- Streamline the electronic processing of REMS prescriptions from prescriber to pharmacy
- SPL "triggers" transaction in prescriber system



ePrescribing for Specialty Medications





Tony Schueth CEO & Managing Partner 954-346-1999 | tonys @pocp.com



www.pocp.com